Obesity is a new study published by Decision Resources, Inc., that reviews current and emerging drugs to treat obesity and evaluates their commercial prospects over a 1999-2009 study period. Our analysis is based on the most recent events in obesity drug development. For example, in July 2000, Roche issued an unofficial warning that sales of orlistat (Xenical), in contrast to many analysts' projections, had slowed in the second quarter of 2000, and the number of new and refill prescriptions had dropped. In addition, Knoll received approval of a method- of-use patent that will extend the market exclusivity of Meridia (sibutramine) for obesity until 2009. Also, the development of beta3-adrenoceptor (B3A) agonists in Europe has stagnated in the past six months. These developments lead us to conclude the following:
-- We believe that the second-quarter results that prompted Roche's warning are a sign of trouble, and that sales of orlistat will weaken over our forecast period. The percentage of drug-treated patients receiving orlistat will decline steadily, especially as sibutramine is launched in Europe and Japan. -- We expect the price of sibutramine to remain stable in the United States, France, and Germany, because the method-of-use patent is not expected to expire until 2009. In Japan, we expect the price of the branded drug to decrease slightly because of reference pricing practices. -- For the United States, we expect sales of B3A agonists to reach $36.1 million in 2004, based on the fact that the two drugs (Pfizer's CP-331684 and Lederle's CL-316243) currently in Phase II development may reach the market in 2004 or earlier, and that they may find a receptive market, given the decline in orlistat's popularity. In Europe, we expect that B3A agonists will enter the market in the second half of our study period, but their late entry will make them minor players in overall European market share through 2009. -- We estimate that major-market sales of pharmaceutical treatments for obesity totaled $490 million in 1999. The continued uptake of sibutramine and orlistat will drive most of the 10% annual growth we expect over our 1999-2009 forecast period. We anticipate that sales of obesity drugs will grow to $1.0 billion in 2004 and then level off by 2009, when sales will reach $1.3 billion.
Obesity is part of Mosaic, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or email@example.com (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com (e-mail).
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc, 781-487-3753,